CONICET | Buscador de Institutos y Recursos Humanos

Human serum Interleukin 6 (IL-6) is a major inducer of acute phase reactions in response to tissue injury, detected in severe inflammatory situations and whose production is influenced by Zinc levels in tissues. However, Zinc excess exacerbates the acute-phase response; thus, it is necessary to control the amount of Zn provided to critical patients receiving Total Parenteral Nutrition (TPN). Therefore, the aim of this work was to study the response of serum Interleukin-6 in relation to plasmatic Zinc (PlZn) and red blood cells Zn levels (RBC Zn) in critical patients (n= 10) receiving TPN after a major abdominal surgery (pancreatitis, pancreas cancer, fistula, and intestinal necrosis). At the beginning (To) and during the patients follow-up (6-21 days), serum IL-6 was determined by ELISA (EASIATM, BioSource, USA); Zn was determined in TPN, in plasma and in red blood cells by Atomic Absorption Spectrometry. The results (mean±standard deviation and ranges) were: Zn provided by TPN (mg/d): 6.9±1.7 (4.8-10.8). Biochemical parameters were, at To: IL-6 (pg/mL): 134±98 (48-465); RBC Zn (ìg/mL): 16±6 (7-27); Pl Zn (ìg/dL) 118±59 (35-226); at Tf: IL-6 (pg/mL): 101±30 (49-150); RBC Zn (ìg/mL): 16±6 (7-27); PlZn (ìg/dL) 122±57 (39-225). There was no correlation between RBC Zn and PlZn nor between variations in serum IL-6 and Pl Zn. Changes in serum IL-6 levels were not in relation to daily Zn administration by TPN. However, IL-6 changes correlated with RBC Zn levels (r= 0.50; p= 0.05). These results show: 1) the influence of RBC Zn levels in the variation of the serum IL-6 levels during the acute response phase; 2) the changes in serum IL-6 levels did not correlate with the daily amount of Zn supplied by TNP in the ranges of this study, which were higher than the values of 2.5 to 5.0 mg/d recommended by ASPEN. Supported by Grant SubCyT, UBA , B103

enviar mensaje